Penn Medicine researchers have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer—and they’ve also proven they have a way to see that feature using PET imaging. The team found PARP inhibitors—a type of targeted therapy that kills cancer cells with mutations in their DNA repair […]

Continue reading »